MST3-IN-1 (TFA)

MST3-IN-1 TFA (Compound LD-1) is a selective and orally active MST3 inhibitor, with an IC50 of 122.4 nM. MST3-IN-1 TFA shows antiproliferative activity against HepG2 cell. MST3-IN-1 TFA effectively induces Apoptosis in HepG2 cells, and halts the cell cycle at the G2/M transition. MST3-IN-1 TFA significantly suppressed tumor growth in HepG2 xenograft mice. MST3-IN-1 TFA can be used for the study of liver cancer[1].

Product Specifications

UNSPSC

12352005

Target

Apoptosis; Bcl-2 Family; Caspase; Hippo (MST)

Related Pathways

Apoptosis; Stem Cell/Wnt

Field of Research

Cancer

Purity

99.38

Smiles

O=C(C1=CN(C2CC2)C3=CC(N4CCNCC4)=C(C=C3C1=O)F)NC5=NC6=C(S5)C=C(OC(F)(F)F)C=C6.OC(C(F)(F)F)=O

Molecular Formula

C27H22F7N5O5S

Molecular Weight

661.55

References & Citations

[1]Li D, et al. Design and synthesis of Riluzole-Ciprofloxacin hybrids as selective MST3 inhibitors for cancer treatment. Eur J Med Chem. 2025 Jun 28;297:117923.